Skip to content

Industry News

Valor Capital and DNA Capital Lead a US$11m Series B in Sanar

14 April 2020

Valor Capital and DNA Capital led a US$11m Series B in Sanar, a Brazilian edtech platform designing customized online training for careers in healthcare, with follow-on from e.bricks Ventures and Vox Capital.


(Press Release) São Paulo, April 2020 – Sanar, a Brazilian MedTech that has the largest online medical education platform in the country, closed its series B round with an investment of US$ 11 million (equivalent to $5,21 at the exchange rate of April 14, 2020), co-led by the investment funds DNA Capital and Valor Capital. The round also had the participation of Vox Capital and e.Bricks Ventures, investors of Sanar in Series A. With the new resources, the startup will expand its staff and make massive investments in technology.

Operating 100% online, Sanar plans to be, in four years, the first company to be present throughout the professional journey of doctors and other health professionals. Today, the startup already has customers in more than 5,000 cities and 7 countries such as Argentina, Paraguay, Bolivia and Portugal.

“Our mission is to offer all the tools for doctors to become super doctors. The demand for these professionals is growing and that is why they should be increasingly productive, humane and will need access to quality content and education”, explains Ubiraci Mercês, CEO of Sanar.

According to Antoine Colaco, a partner at Valor Capital Group, the startup can transform health in a disruptive way. “Sanar serves the medical professional at various stages of their careers, providing high quality information and on multiple platforms”.

The startup understands that doctors are the key to making the health system more efficient. “Today, the health system is complex and inefficient, and a large part of the cost chain decisions in this sector are made by this professional. Increasing their capacity can generate unimaginable gains for society”.

To help fulfill this mission, Sanar has built products for every moment of the medical journey. For students, SanarFlix, an education platform with thousands of contents created by the best teachers in the country. For those who want to take the residency exams, there is the Sanar Medical Residency preparatory course. For the day-to-day necessities of doctors, the company created the Yellowbook, an intelligent guidance app that helps in quick and reliable decision making.

Sanar’s strategy also involves creating online communities with free content and interaction between users. Therefore, the company is able to quickly identify the demands of doctors and then built the production of content in line with what they need or even create new products.

It was through this that Sanar identified, for example, that medical students and doctors in training face financial difficulties during this period. Based on this insight, SanarUp was created, offering financing for those who need extra money to continue their studies.

“Sanar is an example of an innovative company that is making a difference by expanding the frontiers of what is possible to be done in health” says Luiz Henrique Noronha, VC director at DNA Capital.

Combining the knowledge generated from data and behavior analysis with technology makes it possible to create solutions at a level much higher than the market. Vinícius Cogo, pediatrician and part of the Sanar team, comments “We are generating an incredible amount of data on the behavior of doctors and cataloging a vast amount of technical knowledge of medicine”.

While advancing in the construction of solutions for each stage of the doctor’s life, Sanar produces and makes knowledge available free of charge through clinical cases, conduct guides, protocols, classes, scientific articles and a multitude of contents.

That way, the company increasingly consolidates itself as the ideal place to search and offer information for medical practice. In the future, the company wants to be able to assist doctors in real-time consultations, helping to read tests and recommend treatment according to the most up-to-date guidelines, especially for those professionals who operate in places with low health care.

“We believe that man and machine combined will produce medicine from another level. We are only at the beginning of this journey”, adds Ubiraci.